Autoantibody Profiles Of Myasthenia Gravis, Thymoma, and Lambert-Eaton Myasthenic Syndrome

Reasons to Discontinue Testing for AChR Blocking Antibody

May 2012

Previously a test that measured acetylcholine receptor blocking antibodies was offered, but this was to be found of minimal clinical utility because it measures acetylcholine receptor blocking antibody only. The test is positive in 66% of patients with myasthenia gravis with moderate or severe generalized weakness. The test is never positive when acetylcholine receptor binding and modulating antibody tests are negative. The actual test for modulating antibody detects blocking antibody in addition. The blocking antibody test was not additionally informative for thymoma risk. Taking all of the factors into account, it is felt at this point that it is not cost effective.

< Previous Slide

Reasons to Discontinue Testing

Next Slide >

 

Jump to section:

• Introduction
• Serological Diagnostic Algorithms
• 'Hot Topic' Points
• What are MG and LES?
• What are MG and LES?
• MG: Clinical Diagnosis
• MG: Neoplastic Accompaniments
• LES: Clinical Diagnosis
• LES: Electromyography (EMG) Findings
• LES: Neoplastic Accompaniments
• Autoantibodies Aiding MG Diagnosis
• Autoantibodies Aiding MG Diagnosis
• Single Assay Detects AChR Modulating and AChR Blocking Antibody
• Serum AChR Modulating Antibody Values and Interpretation
• Reasons to Discontinue Testing for AChR Blocking Antibody
• Striational Antibodies
• Autoantibodies Detected in MG Patients With Thymoma
• Autoantibodies Aiding the Diagnosis of LES
• Autoantibodies Aiding the Diagnosis of LES
• MGEA/83370 Myasthenia Gravis (MG) Evaluation, Adult Algorithm
• MGEP/83371 Myasthenia Gravis (MG) Evaluation, Pediatric Algorithm
• MGETH/83372 Myasthenia Gravis (MG) Evaluation, Thymoma Algorithm
• MGLES/83369 Myasthenia Gravis (MG)/Lambert-Eaton Syndrome (LES) Algorithm
• Summary
• Questions?